Selank

Enkephalinergic and GABAergic Mechanism Research

The two best-characterized mechanism axes for Selank in the published literature are enkephalin-degrading enzyme inhibition and transcriptional modulation of GABAergic gene expression. Zolotarev et al. (2001) and Kost et al. (2001) reported IC₅₀ values in the 15-20 μM range for Selank inhibition of serum enkephalinase activity^[2][3]. The mechanism is degradation-slowing of endogenous Leu-enkephalin and Met-enkephalin rather than direct opioid-receptor binding.

The GABAergic axis was characterized most rigorously by Volkova et al. (2016) in Frontiers in Pharmacology, using an 84-gene RT-PCR panel across IMR-32 neuroblastoma cells and BALB/c mouse hippocampal tissue^[4]. The paper described expression-level changes across GABA-A subunit transcripts and related interneuron markers following Selank administration. The Volpicelli group at Naples (2017) published the strongest non-Russian-venue replication of the GABAergic gene-expression direction in IMR-32 cells^[7].

Vendor copy characterizing Selank as a GABA-A positive allosteric modulator (PAM) outruns the primary data. The Volkova and Volpicelli papers demonstrate transcriptional regulation of GABAergic gene expression, not direct receptor binding.

Anxiolytic-Context Behavioral Research

Rodent behavioral preparations have been used to investigate Selank in anxiolytic-context research. Standardized assays include elevated plus maze, open field, and Vogel conflict procedures across rat and mouse strains. Kozlovskaya et al. (2003) reported on Selank and short peptides of the tuftsin family in adaptive-behavior preparations under stress conditions, framing the work in terms of behavioral readouts in rat strains with different baseline anxiety phenotypes^[8].

Kasian et al. (2017) published the most-cited independent-venue Selank behavioral paper, examining Selank and diazepam in an unpredictable chronic mild stress (UCMS) preparation in Behavioural Neurology^[9]. This paper is one of the few Selank behavioral preparations published outside Russian-language venues, and the UCMS model is a standardized depression-context preparation rather than a pure anxiety procedure.

Semenova et al. (2009) examined Selank in cognitive-function preparations in rats with different individual behavioral baselines, reporting effects on the dopaminergic system in addition to behavioral readouts^[10]. The behavioral literature has been characterized by small group sizes (typically n=8-15 per arm), short observation windows, and predominantly intranasal administration; few studies use subcutaneous injection, the route at which Selank is sold in the US RUO market.

BDNF and Neurotrophin Research

Inozemtseva et al. (2008) reported the foundational BDNF observations in rat hippocampus following intranasal Selank administration in the 250-to-500-microgram-per-kilogram range^[5]. The paper described BDNF mRNA elevation at 3 hours and BDNF protein elevation at 24 hours, using in-situ hybridization and Western blot detection. The same IMG Moscow group reported parallel BDNF observations for Semax in earlier work, establishing the BDNF axis as one of the candidate mechanisms shared between the two PGP-stabilized analogs.

The Volkova 2016 paper extended the gene-expression panel work to include neurotrophin-related transcripts in mouse hippocampus alongside the GABAergic markers^[4]. Outside the IMG Moscow group, independent Western replication of the rodent BDNF observations remains limited. The Volpicelli 2017 IMR-32 study extended the GABAergic-pathway work but did not replicate the in-vivo hippocampal BDNF observations specifically^[7].

The rodent BDNF observations have not been translated to human pharmacodynamic biomarker studies in the peer-reviewed literature. Whether intranasal Selank produces measurable hippocampal BDNF changes in humans, and whether subcutaneous injectable Selank produces parallel readouts, remain open research questions.

Tuftsin Parent Biology and Immune Research

The endogenous parent peptide tuftsin (TKPR) was discovered in 1970 by Najjar and Nishioka at Tufts University and published in Nature^[1]. Tuftsin is released from the Cγ2 (CH2) domain of the IgG heavy chain at residues 289-292 by spleen tuftsin endocarboxypeptidase, with leukokininase on the neutrophil membrane completing the release. The classical biological activity of tuftsin in the primary literature is immune-modulatory, with reported effects on phagocyte activation, monocyte / macrophage stimulation, and NK-cell function.

Selank was designed at IMG Moscow by appending the C-terminal Pro-Gly-Pro extension to tuftsin, transforming a 4-amino-acid endogenous immune peptide with minutes-scale plasma half-life into a 7-amino-acid synthetic analog with extended protease resistance. The conceptual bridge from tuftsin's immune-modulatory parent biology to Selank's central-nervous-system mechanism observations is not seamless in the literature. The four mechanism axes attributed to Selank (enkephalinase inhibition, GABAergic gene-expression modulation, hippocampal BDNF, monoaminergic turnover) do not inherit cleanly from tuftsin's immune biology, and the mechanism story is multi-pathway rather than receptor-anchored.

The synthesis-stability advantage of the proline-rich architecture is a separate observation that the literature has characterized in some detail. Three internal Pro residues and the C-terminal Pro-Gly-Pro tail block trypsin cleavage after Lys² and Arg⁴ (the canonical Pro rule), and the tail specifically blocks carboxypeptidases and DPP-IV.

Russian Clinical Trial Record and Pivotal Data

The most-cited Selank clinical trial in the published literature is Zozulya and Seredenin et al. (2008) in the Journal of Neurology and Psychiatry imeni S.S. Korsakova, a Russian-language psychiatry journal^[11]. The trial enrolled n=62 participants with generalized anxiety disorder or neurasthenia (a Russian clinical category broader than the Western fatigue diagnosis), with 30 receiving intranasal Selank and 32 receiving medazepam (a Hungarian-developed benzodiazepine used in Russian clinical practice) as an active comparator over 14 days. The trial was open-label, single-site, and not pre-registered. There was no placebo arm.

The total indexed Selank clinical evidence base is approximately 250-400 participants across roughly 3 studies, all conducted in Russian Federation clinical settings, all using the intranasal formulation, all in Russian-language venues. This evidence base is roughly 1-2 orders of magnitude below modern generalized anxiety disorder approval-evidence thresholds, which typically require multiple multi-site placebo-controlled blinded Phase 3 trials with combined participant counts in the thousands.

No active United States or European Union clinical trials of Selank are registered on ClinicalTrials.gov or the EU Clinical Trials Register as of May 2026. The molecule is dormant in Western clinical development; activity is limited to Russian Federation domestic prescribing and research-use channels elsewhere.

Replication, Regulatory Status, and Route Asymmetry

Approximately 70-85% of first or senior authorship in the Selank mechanism and clinical literature traces to the Institute of Molecular Genetics in Moscow and to closely affiliated Russian institutions (V.V. Zakusov Research Institute of Pharmacology, Research Center of Mental Health). The non-Russian mechanism corpus is essentially the Volpicelli 2017 IMR-32 GABAergic gene-expression paper from Naples^[7]. With Igor Ashmarin's death in 2007 and Myasoedov in late-career status, the source-laboratory pipeline is fragile.

The regulatory status of Selank diverges sharply between Russia and Western regulators. Selank was registered by the Russian Ministry of Health in 2009 by JSC Peptogen as a 0.15% intranasal solution for generalized anxiety disorder. Selank is not authorized by the FDA, EMA, MHRA, Health Canada, TGA, or PMDA. The Russian Federation regulatory framework under Federal Law 61-FZ has different evidence requirements than these Western regulators, and Russian Minzdrav registration is not equivalent to FDA approval.

The United States compounding-pharmacy regulatory status is unique among Peerless catalog peptides. Selank was placed on FDA 503A Category 2 (substances that may present significant safety risks) in September 2023, then removed from Category 2 on September 20, 2024 via nominator withdrawal as part of the Evexias / Farmakeio settlement cohort. The Pharmacy Compounding Advisory Committee (PCAC) has never voted on Selank: Selank was not on the October 29, 2024 PCAC docket, not on the December 4, 2024 docket, not in the April 22, 2026 reclassification batch, and is not on the July 23-24, 2026 PCAC docket. Status as of May 2026 is limbo: removed from Category 2 without an affirmative bulks-list vote either confirming or rejecting compoundability.

A separate methodology consideration is route asymmetry. Every published Russian clinical study used the intranasal 0.15% solution. The 92.8% bioavailability and 2-3 minute plasma half-life figures in the published pharmacokinetic literature are intranasal. The US laboratory research market sells Selank as a subcutaneous lyophilized vial, a different administration route than the studied evidence supports, with no peer-reviewed human pharmacokinetic or efficacy study of subcutaneous injectable Selank in the indexed literature.